S1 Guideline: Diagnosis and therapy of skin leishmaniasis and mucocutaneous leishmaniasis in Germany;S1-Leitlinie Diagnostik und Therapie der kutanen und mukokutanen Leishmaniasis in Deutschland

JDDG - Journal of the German Society of Dermatology

Volumn 7, Issue SUPPL. 7, 2009, Pages

  Boecken, Gerhard ^a   Weitzel, Thomas ^b   Sunderkötter, Cord ^c   Fischer, Marcellus ^d   Von Stebut Boschitz, Esther ^e   Bogdan, Christian ^f   Pietras, Mathias ^g   Anders, Gerlind ^h   Harms Zwingenberger, Gundel ^b   Burchard, Gerd ⁱ   Bialek, Ralf ^j   Lippert, Ute ^k   Grobusch, Martin ^l   Erkens, Kay ^m   Fleischer, Bernhard ^d   Löbermann, Micha ⁿ   Schunk, Miriam ^o   Sterzik, Barbara ^p  

^a Schulungs/Beratungszentrum Berlin   (Germany)

^b Institut fur Tropenmedizin   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^e UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^f UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^g Eterna Zentaris GmbH   (Germany)

^h Sybelstr6a   (Germany)

ⁱ UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^j MVZ Labor Dr Krause und Kollegen   (Germany)

^k Ohlenkamp 2   (Germany)

^l UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^m Dezernat Tropenmedizin   (Germany)

ⁿ UNIVERSITY OF ROSTOCK   (Germany)

^o LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^p Bundesinstitut fur Arzneimittel und Medizinprodukte   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMINOGLYCOSIDE; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY DERIVATIVE; AZITHROMYCIN; CANEX; FLUCONAZOLE; FOSCARNET; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIQUIMOD; ITRACONAZOLE; KETOCONAZOLE; LESHCUTAN; MEGLUMINE ANTIMONATE; MILTEFOSINE; OMEPRAZOLE; PAROMOMYCIN; PENTAMIDINE ISETHIONATE; PENTOXIFYLLINE; RIFAMPICIN; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ABSCESS; ACUTE KIDNEY FAILURE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLERGIC REACTION; ALLERGY; ALOPECIA; AMERICAN LEISHMANIASIS; ANAPHYLACTIC SHOCK; ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; ANOREXIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BLISTER; BURNING SENSATION; CARDIOTOXICITY; CHILL; COLLAPSE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIARRHEA; DIPLOPIA; DIZZINESS; DYSPEPSIA; FEVER; FLATULENCE; FLU LIKE SYNDROME; FLUSHING; GASTROINTESTINAL SYMPTOM; GERMANY; HEADACHE; HEARING LOSS; HEART ARRHYTHMIA; HEPATITIS; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERMAGNESEMIA; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPERTHERMIC THERAPY; HYPOCALCEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPOTENSION; INJECTION SITE PAIN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LEUKOPENIA; LIVER DYSFUNCTION; LIVER FAILURE; LIVER FUNCTION TEST; MACULOPAPULAR RASH; MEDICAL PRACTICE; MENSTRUATION DISORDER; MYALGIA; NAUSEA; NEPHROTOXICITY; PANCREAS NECROSIS; PANCREATITIS; PERIPHERAL NEUROPATHY; PHOTODYNAMIC THERAPY; PHOTOPHOBIA; PRACTICE GUIDELINE; PRURITUS; PURPURA; QT PROLONGATION; RASH; RHABDOMYOLYSIS; SHOCK; SIDE EFFECT; SKIN ATROPHY; SKIN INDURATION; SKIN INFLAMMATION; SKIN IRRITATION; SKIN LEISHMANIASIS; SKIN MANIFESTATION; TASTE DISORDER; THROMBOCYTOPENIA; TINNITUS; TORSADE DES POINTES; UREA BLOOD LEVEL; UREMIA; URTICARIA; VISUAL DISORDER; VOMITING; CLINICAL PRACTICE; DERMATOLOGY; STANDARD;

DERMATOLOGY; GERMANY; HUMANS; LEISHMANIASIS, CUTANEOUS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC;

MLCS; MLOWN;

EID: 73449097537     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2009.07179.x     Document Type: Article

References (300)

1. Akilov O, Khachemoune A, Hasan T. Clinical manifestations and classification of OWCL. IntJ Dermatol 2007; 46, 132-142.
2. Albanese G, Giorgetti P, Santagostino L, Crippa D, Sala G. Cutaneous leishmaniasis. Treatment with itraconazole. Arch Dermatol 1989; 125(11): 1540-1542.
3. Aleixo J, Nascimento E, Monteiro G, Fernandes M, Ramos A, Wilson M, Pearson R, Jeronimo S. Atypical American VL caused by disseminated Leishmania amazonensis infection presenting with hepatitis and adenopathy. Trans R Soc Trop Med Hyg 2006; 100:79-82. (Pubitemid 41700196)
4. Al-Fouzan A, Al Saleh Q, Najem N, Rostom A. Cutaneous Leishmaniasis in Kuwait Clinical Experiences with Itraconazole. Int J Dermatol 1991; 30(7): 519-521.
5. Alkhawajah A. Treatment of CL with antimony: intramuscular versus intralcsional administration. Ann Trop Med Parasitol 1997; 91(8): 899-905. (Pubitemid 28019791)
6. Allen S, Neal R. In vitro anti-Leishmanial activity of compounds in current clinical use for unrelated diseases. Drugs Exp Clin Res 1.988; 14(10): 621-628.
7. Al-Majali O, Routh H, Abuloham O, Bhowmik. K, Muhsen M, Hcbeheba H. A 2-year study of liquid nitrogen therapy in CL. Int J Dermatol 1997; 36: 460-462.
8. Almeida R. Randomized, double blind study of Stibogluconate Plus Human Granulocyte Macrophage Colony-Stimulating Factor versus Stibogluconate Alone in the Treatment of CL. J Infect Dis 1999; 180: 1735-1737. (Pubitemid 29506486)
9. Almeida R, Brito J, Machado P, de Jesus A Schriefer A, Guimaraes L, Carvalho E. Sucessful treatment of refractory CL with GM-CSF and. antimonials. AmJ Trop Med Hyg 200,5; 73(1): 79-81.
10. Alrajhi A. Fluconazole for the Treatment of CL caused by Leishmania major. N Engl J Med 2002; 346(12): 891-895.
11. Alsaleh A, Dvorak R, Nanda A. Ketoconazole in the treatment of CL in Kuwait. IntJ Dermatol 1995; 34(7): 495-497.
12. Alvar J, Croft S, Olliaro P. Chemotherapy in the Treatment and Control of Leishmaniasis. Adv Parasitol 2006; 61:224-274.
13. Amato V, Tuon F, Siqueira A, Nicodemo A, Neto V Treatment of Mucosal Leishmaniasis in Latin America: Systematic Review. Am J Trop Med Hyg 2007; 77(2): 266-274. (Pubitemid 351859275)
14. Amato V et al. Mucocutaneous leishmaniasis associated with HIV infection treated successfully with liposomal amphotericin B (AmBisome). J Antimicrob Chemother 2000; 46: 341-342. (Pubitemid 30639320)
15. Amato V1 Rabcllo A, Rotondo-Silva A, Kono A, Maldonado T, Alves I, Floeter-Winter L, Neto V, ShikanaiYasuda M. Successful treatment of cutaneous leishmaniasis with lipid, formulations of amphotericin B in two immunocompromised patients. Acta Tropica 2004; 92(2): 127-132. (Pubitemid 39180014)
16. Amato V et al. Treatment of mucosal leishmaniasis with a lipid formulation of Amphotericin B. Clin Infect Dis 2007;44:311-312.
17. Amato V, Tuon F, Siqueira A et al. Treatment of MCL in Latin America: systematic review. Am J Trop Med. Hyg 2007; 77(2): 266-274.
18. Ameen M. CL: therapeutic strategies and future directions. Expert Opin Pharmacother 2007; 8(16): 2689-2699.
19. Andersen E. Comparison of Meglumine Antimoniate and Pentamidine for Peruvian CL. Am J Trop Med Hyg 200,5; 72(2): 133-137.
20. Andrade-Narváez F. Clinical picture of CL due to L.(L.) mexicana in the Yucatan. Peninsula, Mexico. Mem Isnt Oswaldo Cruz 2001; 96(2): 162-167.
21. Andres C. Entscheidend in der primären Immunantwort. Der deutsche Dermatologe 2006; 2: 93-96.
22. Annonymous. Control of Leishmaniases. WHO Technical Report Series 1990;793:1-159.
23. Antinori S, Calattini E, Longhi E, Gramiccia M, Corbellino M. CL: an increasing threat for travellers. Clin Microbiol Infect 2005; 11: 343-346.
24. Antoniou M. Short Report: Treatment failure due to mixed. Infection by different Strains of the Parasite Leishmania infantum. Am J Trop Med Hyg 2004; 71(1): 71-72. (Pubitemid 38902647)
25. Aram H, Lcibovici V Ultrasound-induced Hyperthermia in the treatment of CL. Cutis 1987; 40: 350-353.
26. Arana B. Randomized, controlled, doubleblind trial if Topical treatment of CL with Paromomycin plus Methylbenzethonium Chloride ointment in Guatemanla. Am J Trop Med. Hyg 2001; 65(5): 466-470. (Pubitemid 33134578)
27. Arana B. Chemotherapy of CL: a review. Med Microbiol Immunol 2001; 190: 93-95.
28. Ardehali S. The characterization of Leishmania from patients with lymphadenopathy in Shiraz, Iran. Trans R Soc Trop Med Hyg 1995; 89: 370-371.
29. Arevalo J. Successful Treatment of Drug-Resistant CL in Humans by Use of Imiquimod, an Immunomodulator. Clin Infect Dis 2001; 33: 1847-1851.
30. Arevalo J, Ramirez L, Adaui V, Zimic M, Tulliano G et al. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary Leishmaniasis. J Infect Dis 2007; 195: 1846-1851.
31. Arevalo J, Tulliano G, Quispe A, Spaeth G, Matlashewski G, LlanosCuentas A, Pollack H. Role of imiquimod and parenteral meglumine antimonite in the initial treatment of CL. Clin Infect Dis 2007; 44:1549-1554. (Pubitemid 46871500)
32. Armijos R. Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World CL. Vaccine 2003; 1320-1326.
33. Armijos R, Weigel M, Calvopina M, Mancheno M, Rodriquez R. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World. CL. Acta Tropica 2004; 91(2): 153-160. (Pubitemid 38952716)
34. Aronson N, Wortmann G, Johnson S, Jackson J, Gasser R, Magill A, Endy T, Coyne P, Grogl M, Benson P, Beard J, Tally J, ,Gambel J, Kreutzer R, Oster C. Safety and Efficacy of Intravenous Sodium Stibogluconate in the Treatment of Leishmanisis: Recent U.S. Military Experience. Clin Infect Dis 1998; 27: 1457-1464. (Pubitemid 29242421)
35. Aseri S. The role of rifampicin in the management of CL. QJM 2000; 93: 733-737.
36. Asilian A. Sadeghinia A, Faghihi G, Momeni A, Harandi A. The efficacy of treatment with intralcsional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of CL. Ann Trop Med Parasitol 2003; 97(5): 493-498. (Pubitemid 36898085)
37. Asilian A. Treatment of CL with aminosidinc (paromomycin) ointment: doubleblind, randomized trial in the Islamic Republic of Iran. Bulletin WHO 2003; 81(5): 353-359. (Pubitemid 36644261)
38. Asilian A, Davami M. Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of OWCL: a placebocontrolled, randomized clinical trial. Clin Exp Dermatol. 2006; 31(5): 634-637.
39. Asilian A, Jalayer T, Whitworth J, Ghasemi R, Nilforooshzadeh M, Olliaro P. A randomized, placebo controlled trial of a two-week regimen of Aminosidine (Paromomycin) Ointment for Treatment of CL in Iran. Am J Trop Med Hyg 1995; 53(6): 648-651. (Pubitemid 26036354)
40. Asilian A, Sadeghinia A, Faghihi G, Momeni A. Comparative study of the efficacy of combined, cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate alone for. IntJ Dermatol. 2004; 43(4): 281-283.
41. Azeredo-Coutinho RB, Mendonça SC, Callahan H, Portal. AC, Max G. Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis. J Parasitol 2007; 93(3): 688-693. (Pubitemid 47036094)
42. Badaro R. The Role of Interferon in the Treatment of VL and DCL. J Infect Dis 1993; 167(Suppl 1): 13-17.
43. Bafica A, Oliveira F, Freitas L, Nascimento E, Barrai A. ACL unresponsive to antimonal drugs: successful treatment using combination of N-Methylglucantime Antimonate plus Pentoxifylline. Int J Dermatol 2003; 42: 203-207. (Pubitemid 41709833)
44. Bailey M. Clinical Guidelines for the Management of CL in British Military Personnel. J R Army Med Corps 2005;151:73-80.
45. Bailey M., Lockwood D. CL. Clin Dermatol 2007; 2,5(2): 203-211.
46. Bailou W, McClain J, Gordon D, Shanks G, Andujar J, Berman J, Chulay J. Safety an efficacy of highdose sodium stibogluconate therapy of Ameriacan CL. Lancet 1987; 2(8549): 13-16.
47. Banzet S. Epidemics of CL in military personnel working in French Guiana. Med Trop (Mars) 2000; 60(3): 297-302.
48. Barrai A, Barral-Nctto M., Almeida R, Ribeiro de Jesus A, Grimaldi G, Netto E, Santos I, Baccllar O, Carvalho E. Lymphadenopathy associated with Leishmanis braziliensis cutaneous infection. Am J Trop Med Hyg 1992; 47(5): 587-592.
49. Barrai A, Guerreiro J, Bohmfim G, Corrcira D, Barral-Netto M, Carvalho A. Lymphadenpathy as the first sign of human cutaneous infection by Leishmania braziliensis. Am J Trop Med Hyg 1995; 53(3): 256-259.
50. Barrai A, Pedral Sampaio D, Grimaldi G, Momen H, McMahonPratt D, Ribeiro A, Almeida R, Badardo R, Barral Netto M, Carvalho E. Leishmaniasis in Bahia, Brazil: evidence that Leishmania amazonensis produces a wide spectrum of clinical disease. Am J Trop Med. Hyg 1991; 44(5): 536-546.
51. Baumm K, Berens R. Successful treatment of CL with Allopurinol after failure of treatment with ketoconazole. Clin Infect Dis 1994; 18: 813-815. (Pubitemid 24145923)
52. Belkaid Y. The role of interleukin (IL) - 10 in the persistence of Leishmania major in the Skin after Healing and the Therapeutic Potential of Anti- IL-10 Receptor Antibody for Sterile Cure. J Exp Med 2001; 194(10): 1497-1506. (Pubitemid 33081524)
53. Belli A. Simplified Polymerase Chain Reaction Detection of New World. Leishmania in Clinical Specimens of CL. Am J Trop Med Hyg 1998; 58(1): 102-109. (Pubitemid 28071418)
54. Ben Salah A, Zakraoui H, Zaatour A, Ftaiti A, Zaafouri B, Garraoui A, Olliaro P, Dellagi K, Ben I. A randomized, placebo-controlled trial in Tunisia treating CL with paromomycin ointment. Am J Trop Med. Hyg 1995; 53(2): 162-166.
55. Berman J. Human Leishmaniasis: Clinical, Diagnostic, and Chcmotherapeutic Developments in the last 1.0 Years. Clin Infect Dis 1997; 24: 684-703.
56. Berman J. Recent Developments in Leishmaniasis: Epidemiology, Diagnosis, and Treatment. Current Infectious Dis Rep 2005; 7: 33-38.
57. Berman J. Current treatment approaches to Leishmaniasis. Current Opinion in Infect Dis 2003; 16: 397-401.
58. Berman J, Chulay J, Hendricks L, Oster C. Susceptibility of clinically sensitive and resistant leishmania to pentavalent antimony in vitro. Am J Trop Med Hyg 1.982; 31(3): 459-465.
59. Berman J, Neva F. Effect of temperature on multiplication of Leishmania amastigotes within human monocytc-derived macrophages in vitro. Am J Trop Med Hyg 1981; 30(2): 318-321. (Pubitemid 11117216)
60. Berman J, Bryceson A, Croft S, Engel J, Guttcridgc W, Karbwang J, Sindermann H, Soto J, Sundar S, Urbina J. Miltefonsine: issues to be addressed in the future. Trans R Soc Trop Med Hyg 2006; 100S: S41-44.
61. Bhattacharya S, Jha T, Sundar S, Thakur C, Engel J, Sindermann H, Junge K, Karbwang J, Bryceson A, Bermann J. Efficacy and Tolerability of Miltefosine for Childhood Visceral Leishmaniasis in India. Clin Infect Dis 2004; 38: 217-221. (Pubitemid 38113029)
62. Blum J. Therapie kutaner und mukokutaner Leishmaniosen. Dtsch Med Wschr 1994; 119: 1169-1172.
63. Blum. J. Treatment of CL among travellers. J Antimicrob Chem 2004; 53: 158-166.
64. Boakye D, Wilson M, Kweku M. A Review of Leishmaniasis in West Africa. Ghana Med J. 2005; 39(3): 94-97.
65. Bormann G. Kutane amerikanische Leishmaniose - Besonderheiten der Diagnostik und Therapie. Dtsch. Med Wschr2003; 128: 2065-2068.
66. Brito M. Dynamics of the antibody response in patients with therapeutic or spontaneous cure of American CL. Trans R Soc Trop Med. Hyg 2001 ; 95 : 203-206. (Pubitemid 34947389)
67. Brown M, Noursadeghi M, Boyle J, Davidson R. Successful liposomal amphotericin B treatment of Leishmania braziliensis CL. Br J Derm 2005; 153: 203-205.
68. Bryceson A, Murphy A, Moody A. Treatment of Old World CL with aminosidine ointment: results of an open, study in London. Trans R Soc Trop Med Hyg 1994; 88: 226-228. (Pubitemid 24139698)
69. Burbach G. Leishmaniosen Grundlagen, Klinik, Diagnostik und Therapie. Dtsch Med Wschr 1999; 124: 88-93.
70. Calvopina M, Gomez E, Sindermann H, Cooper P, Hashiguchi Y Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment. Am J Trop Med Hyg 2006; 75(6): 1074-1077. (Pubitemid 351627483)
71. Calvopina M, Guevara A, Armijos R, Hashiguchi Y, Davidson R, Cooper P. Itraconazole in the treatment of New World mucocutaneous leishmaniasis. Int J Dermatol 2004; 43(9): 6,59-63.
72. Calvopina M, Uezato H, Gomez E, Korenaga M, Nonaka S, Hashiguchi Y Leishmania recidiva cutis due to Leishmania (V) panamensis in subtropical Ecuador: isoenzymatic characterization. Int J Dermatol 2006; 45: 116-120.
73. Calza L, D'Antuono A, Marinacci G et al. Disseminated, cutaneous leishmaniasis after visceral disease in a patient with AIDS. J Am Acad Dermatol 2004; 50(3): 461-465.
74. Campos-Muñoz L et al. Leishmania braziliensis: report of a pediatric imported case with response to liposomal amphotericin B. Acta Dermosifiliogr 2007; 98(1): 42-44.
75. Canaan T. Die Jerichobeule. Zentralblatt f. Bakteriologie 1914; 73: 110-119.
76. Cardo L. Leishmania: risk for the blood supply. Transfusion 2006; 46: 1641-1645.
77. Carvalho EM, Barrai A, Costa JM, Bittencourt A1 Marsden P. Clinical and immunopathological aspects of disseminated cutaneous leishmaniasis. Acta Trop 1994; 56(4): 315-325.
78. Catorze G, Alberto J, Afonso A, Vieira R, Cortes S, Campino L. Cutaneous lesions following treatment of VL. Ann Dermatol Venerol 2006; 133(1): 39-42.
79. Chulay J, Spencer H, Mugambi M. Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony. Am J Trop Med Hyg 1985; 34(4): 702-709.
80. Clos J. Proceedings of an International Workshop held at the Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany, 10.-11. Nov. 2000. Med Microbiol Immunol 2001; 190: 1.-2. (Pubitemid 33079347)
81. Colmenares M, Kar S, GoldsmithPestana K, McMahon-Pratt D. Mechanisms of pathogenesis: differences among Leishmania species. Trans R Soc Trop Med Hyg 2002; 96: S1/3-S1/7.
82. Consigli J, Danielo C1 Gallerano V, Papa M, Guidi A. CL: Successful treatment with itraconazole. Int J Dermatol 2006; 45: 46-49.
83. Convit J. Leishmaniasis: Immunological and clinical aspects and vaccines in Venezuela. Clinics in Dermatology 1996; 14(5): 479-487. (Pubitemid 26327741)
84. Costa J. O Uso Clinico das pentamidine Com especial referencia nas Leishmanioscs. Acta Amazónica 1993; 23(2-3): 163-172.
85. Costa J, Manden PD, LlanosCuentas EA, Netto EM, Carvalho EM, Barrai A, Rosa AC, Cuba CC, Magalhães AV, Barreto AC. Disseminated, cutaneous leishmaniasis in a field clinic in Bahia, Brazil: a report of eight cases. J Trop Med Hyg 1986; 89(6): 319-323. (Pubitemid 17230044)
86. Croft S. Chemotherapy of Leishmaniasis. Curr Pharm Des 2002; 8(4): 319-342.
87. Croft S. Drug sensitivity of CL species: some unresolved, problems. Trans R Soc Trop Med Hyg 2002; Suppl. 1 : 127-129.
88. Croft S. Chemotherapy of Trypanosomiasis and CL. TRENDS in Parasitology 200,5; 20(20): 1-6.
89. Croft S. CL - current chemotherapy and recent advances in the search for novel drugs. TRENDS in Parasitology 2003; 19(11): 502-508. (Pubitemid 37329659)
90. Croft S, Davidson, R, Thornton E. Liposomal amphotericin, B in the treatment of visceral leishmaniasis. J Antimicrob Chemoth 1991; 28: 111-118.
91. Croft S, Sundar S, Fairlamb A. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006; 19(1): 111-126.
92. Cruz A, Rainey P, Herwaldt B, Stagni G, Palacios R, Trujillo R, Saravia N. Pharmacokinetics of Antimony in children treated, for Leishmaniasis with meglumine antimoniate. J Infect Dis 2007; 195: 602-608. (Pubitemid 46214405)
93. Davidson R. A topical nitric oxide generating therapy for CL. Trans R Soc Trop Med. Hyg 2000; 94: 19-322.
94. Davidson R. Leishmaniasis. Infect Dis 1999; 2: 32.1-32.6.
95. Davidson R, Martino L, Gradoni L, Giacchino Ret al. Liposomal amphotericin B (AmBisome) in Mediterra- nean VL: a multi-centre trial. Q J Med 1994; 87: 75-81.
96. Davidson R, Croft S. Recent advances in the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg 1993; 87: 130 f.u. 140.
97. Davidson. R, Croft S, Scott A et al. Liposomal amphotericin B in drug - resistant visceral leishmaniasis. Lancet 1991; 337: 1061-1062.
98. De Oliveira Camera P, Junger J, do EspiritoSanto Silva Pires F Mattos M, Olivcria-Ncto M, Fernandes O, Pirmez C. Haematogenous dissemination of Leishmania (Viannia) braziliensis in human American, tegumentary leishmaniasis. Trans R Soc Trop Med Hyg 2006;100:1112-1117.
99. De Oliveira Schubach A. Retrospective study of 151 patients with CL treated with meglumine antimoniate. Rev Soc Bras Med Trop 2005; 38(3): 213-217.
100. De Vries P, van der Meide W, Godfried M, Schallig H, Dinant H, Faber W Quantification of the response to miltefosine for VL by QT-NASBA. Trans R Soc Trop Med Hyg 2006; 100: 1183-1186.
101. st edition. 2004; Chapter 7.5: 1339 ff.
102. Dedet, J-P. CL in. French Guiana; a Review. Am J Trop Med Hyg 1990; 25-28: 89-147.
103. Delobel P. Rhabodomyolysis associated with pentamidine isethionate therapy for ACL. J Antimicrob Chem 2003; 51: 1319-1320.
104. Desjeux: P. Worldwide increasing risk factors for Leishmaniasis. Med Microbiol Immunol 2001; 190: 77-79.
105. Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg 2001; 95: 239-243. (Pubitemid 33713068)
106. Dogra J, Aneja N, Behari B, Nath Mishra S. CL in India Clinical Experience with Itraconazole. Int J Dermatol 1990; 29(9): 661-662.
107. Dogra J, Saxena V Itraconazole and leishmaniasis: a randomized doubleblind trial in cutaneous disease. Int J Parasitol 1996; 26(12): 1413-1415. (Pubitemid 27062527)
108. Dowlati Y CL: clinical aspects. Clinics in. Derm. 1.996; 14:425-431.
109. Elamin E. Uncommon clinical presentation of CL in Sudan. Trans R Soc Trop Med Hyg 2005; 99: 803-808.
110. El-Darouti M. CL. Treatment with combined cryotherapy and intralesional stibogluconate injection. Int J Dermatol 1990; 29(1): 56-59. (Pubitemid 20136326)
111. El-Hajj L, Thellier M, Carriere J, Bricaire F, Danis M, Caumes E. Localized CL imported into Paris: a review of 39 cases. Int J Dermatol 2004; 43: 120-125.
112. El-Hassan A. Leishmaniasis in Sudan: 1. CL. Trans R Soc Trop Med Hyg 2001; Suppl. 1: 1-17.
113. El-Hassan A. Sudanese mucosal, lcishmaniasisxpidemiology, clinical features, diagnosis, immune responses and treatment. Trans R Soc Trop Med Hyg 1995; 89: 647-652. (Pubitemid 26016350)
114. El-On J, Bazarsky E, Sneir R. Leishmania major: in vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined, with the immunomodulator Imiquimod. Exp Parasitol 2007; 116(2): 156-162. (Pubitemid 46602257)
115. El-On J. Topical Chemotherapy of CL. Parasitology Today 1988; 4(3): 76-81.
116. El-On J Cawich F, Evans D, Weinrauch L. Topical treatment of CL in Belize:in vitro and in vivo studies with Leishmaniasis mexicana. Int J Parasitol. 1993; 23(1): 121-127. (Pubitemid 23105176)
117. El-On J Jacobs G, Witztum E, Greenblatt C. Development of topical treatment for CL caused by Leishmania major in experimental animals. Antimicrob Agents Chemother 1.984; 26(5): 745-751.
118. El-On J, Halevy S, Grunwald M, Weinrauch L. Topical treatment of OWCL caused by Leishmania major: A double-blind control study. J Am Acad. Dermatol 1992; 27: 227-231.
119. El-On J, Livshin R, Even-Paz Z, Hamburger D, Weinrauch L. Topical Treatment of CL. J Invest Dermatol 1986; 87: 284-288.
120. El-On J, Livshin R, Even-Paz Z, Weinrauch L. Topical Treatment of CL. BMJ 1985; 291: 1280-1281.
121. El-On J, Messer G. Leishmania major: Antileishmanial activity of Methylbenzethonium chloride. Am J Trop Med Hyg 1986; 1110-1116.
122. El-On J, Sulitzcanu A, Schnur L. Leishmania major: resistance of promastigotes to paromomycin, and susceptibility of amastigotes to paromom.ycin-methylbenzethon.ium. chlorid ointment. Ann Trop Med Parasitol 1991; 85(3): 323-328.
123. El-Safi S, Murphy A, Bryceson A, Neal R. A double-blind clinical trial of the treatment of CL with paromomycin ointment. Trans R Soc Trop Med Hyg 1990; 84: 690-691.
124. Enk C, Fritsch C, Jonas F, Nasercddin A, Ingber A, Jaffe C, Ruzicka T. Treatment of cutaneous leishmaniasis with photodynamic therapy. Arch Dermatol 2003.; 139: 432-434.
125. Escobar P. Sensitivities of CL species to hexadecylphosphocholine (miltcfosine), ET-18-OCH (edclfosine) and amphotericin B. Acta Tropica 2002; 81:151-157. (Pubitemid 34093805)
126. Escobar P, Yirdley V, Croft S L. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient seid mice. Antimicrob Agents Chemother 2001; 45(6): 1872-1875.
127. Esfandiarpour I, Alavi A. Evaluating the efficacy of allopurinol and meglumine antimoniate (Glucantime) in the treatment of CL. Int J Dermatol 2002; 41(8): 521-524. (Pubitemid 35021497)
128. Evans D. Handbook on Isolation, Characterization and Cryopreservation of Leishmania. TDR, UNDP/ Worldbank/WHO 1989; 1-45.
129. Faghihi G. Treatment of CL with either topical paromomycin or intralesional meglumine antimoniate. Clin Exp Dermatol 2003; 28(1): 13-16. (Pubitemid 36197553)
130. Faris R, Jarallah J, Khoja T, al-Yamani M. Intralesional treatment of CL with sodium stibogluconate antimony. Int J Dermatol 1.993; 32(8): 610-612.
131. Firooz A. Intralesional injection of 2 % zinc sulfate solution in the treatment of acute OWCL: a randomized, double-blind, controlled clinical trial. J Drugs Dermatol 2005; 4(1): 73-79.
132. Firooz A, Khamesipour A, Ghoorchi M, Nassiri- Kashani M, Eskandari S, Khatami A, Hooshmand B, Gorouhi F1 Rashighi-Firoozabadi M, Dowlati Y Imiquimod in combination with meglumine antimoniate for CL: a randomized assessor-blind controlled, trial. Arch Dermatol 2006; 142(12): 1575-1579. (Pubitemid 44969213)
133. Firooz A, Khatami A, Dowlati Y. Itraconazole in the treatment of CL. Int J Dermatol 2006; 45: 1446-1447.
134. Fischer C. Development status of miltefosine as first oral drug in visceral an CL. Med. Microbiol Immunol 2001; 190:85-87.
135. Franke E. Efficacy and Toxicity of Sodium Stibogluconate for MCL. Ann Int Med 1990; 113(12): 934-940.
136. Frankcl D. Study puts a number on. poor compliance in the elderly. Lancet 1998; 351: 1495.
137. Gadelha A, Oliveira W, Ass uncao I, Dourado H. Tratamento da leishmaniose tegumentar americana com injecoes intralcsionais de n-metilglucamina. Ann Bras Dermatol 1990; 65(4): 201-203.
138. Garcia A, Parrado R, de Doncker S, Bermudez H, Dujardin H. American, tegumentary Leishmaniasis: direct species identification of Leishmania in. non-invasive clinical samples. Trans R Soc Trop Med Hyg 2006.
139. Gardlo K, Hanneken S, Ruzicka T, Neumann N. Photodynamic therapy of cutaneous leishmaniasis. A promising new therapeutic modality. Hautarzt 2004; 55: 381-383.
140. Gardlo K, Horska Z, Enk C, Rauch L, Megahed M, Rudzicka T, Fritsch C. Treatment of CL by photodynamic therapy. J Am Acad Dermatol 2003; 48: 893-896.
141. Garnier T, Croft S. Topical. Treatment for CL. Current Op Invest Drugs 2002; 3(4): 538-544.
142. Gasser RA Jr, Magill AJ, Oster CN, Franke ED, Grogl M, Berman JD. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis 1994; 18(1): 83-90.
143. Ghosn S. Evaluation of sodium stibogluconate in the treatment of CL in. Syria. CurrMedRes Opin 1979; 6(4): 280-283.
144. Gontijo B. Leishmaniose tegumentar americana American CL. Rev Soc Bras Med Trop 2003; 36(1): 71-80.
145. Gradoni L. Visceral Leishmaniasis Treatment, Italy. Emerging Infect Dis 2003; 9(12): 1617-1620.
146. Grevelink S, Lerner E. Leishmaniasis. J Am Acad Dermatol 1996; 34: 257-272.
147. Grimaldi G, Schottelius J. Leishmaniasis - Their relationships to monoxenous and dixenous trypanosomatids. Med Microbiol Immunol 2001; 190:3-8. (Pubitemid 33079348)
148. Grimaldi G, Tesh R. Leishmaniases of the New World: Current Concepts and Implications for Future Research. Clin Microbiol Reviews 1993; 230-250.
149. Grimaldi G, Tesh R, McMahon-Pratt D. A review of the geographic distribution, and epidemiology of Leishmaniasis in the New World. Am J Trop Med Hyg 1989; 41(6): 687-725. (Pubitemid 20022744)
150. Groll A. Failure of Amphotericin B Lipid Complex in the Treatment of CL. Clin. Infect Dis 1998; 26: 1.006 f.
151. Guderian R, Chico M, Rogers M, Pattishall K, Grogl M, Berman J. Placebo controlled Treatment of Ecuadorian CL. Am J Trop Med Hyg 1991; 45(1): 92-97.
152. Gunduz K. Recidivans CL unresponsive to liposomal amphotericin B (AmBisome). J Eur Acad Dermatol Venereol 2000; 14(1): 11-13.
153. Gurei M, Tatli N, Ozbilge H, Erel O, Seyrek A, Kocyigit A, Ulukanligil M. Efficacy of cryotherapy and intralesional pentostam in treatment of CL. J Egypt Soc Parasitol 2000; 30(1): 169-176.
154. Gurel M, Ulukanligil M, Ozbilge H. Cutaneous leishmaniasis in Sanliurfa: epidemiologic and clinical features of the last four years (1997-2000). Int J Dermatol 2002; 41: 32-37.
155. Gustavo A. Comparison of CL Due to Leishmania (Viannia) braziliensis and L.(V.) guyanenesis in Brazil: Clinical Findings and Diagnostic Approach. Current Infect Dis 2001; 32: 1304-1312.
156. Hadighi R, Mohebali M, Boucher P, Hajjaran H, Khamesipour A, Quellette M, Unresponsiveness to Glucantime Treatment in Iranian CL due to Drug - Resistant Leishmania tropica Parasites. Plos Med 2006; 3(5): 1-9.
157. Handman E. Leishmaniasis: Current Status of Vaccine Development. Clinical Microbiol Reviews 2001; 14(2): 229-243.
158. Harms G. A randomized trial comparing a pentavalent antimonial drug and recombinant interferon in the local treatment of CL. Trans R Soc Trop Med Hyg 1991; 85: 214-216.
159. Harms G. Leishmaniosen - Importierte Krankheiten. Deutsches Ärtzeblatt 2000; 31-32: 1589-1592.
160. Harms G, Chehade A, Racz P, Douba M, Naiff R, Fcldmcicr H, Zwingenberger K, Talhari S, Mouakeh A, Näkel L, Kremsner P, Bienzle U. Effects of intradermal Gamma-Interferon in CL Lancet 1989; 10: 1287-1292.
161. Harris E. Single-Step Multiplex PCR Assay for Characterization of New World Leishmania Complexes. J Clinical Microbiology 1998; 36(7): 1989-1995.
162. Hartzeil J, Aronson N, Ngaraja S, Whitman. T, Hawkes C, Wortmann G. Varizella Zoster Vims Meningitis complicating sodium stibogluconate treatment for CL. Am J Trop Med Hyg 2006; 74(4): 591-592. (Pubitemid 46774438)
163. Heinzl. S. Amphotericin B. Arzncimitteltherapic 1995; 20: 1-8.
164. Hellier I. Treatment of OWCL by Pentamidine Isethionatc. Dermatology 2000; 200: 120-123.
165. Hepburn N. CL: Current and futuremanagement. Expert Rev Anti-infect Ther 2003; 1(4): 563-570.
166. Hepburn N, Tidman M, Hunter J. Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of ACL. Trans R Soc Trop Med. Hyg 1994; 88: 700-703.
167. Hepburn N. CL. Clin Exp Dermatol 2000; 25: 363-370.
168. Herwaldt B. Recommendations for treating Leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. AmJ Trop Med Hyg 1992; 46(3): 296-306.
169. Herwaldt B. Miltefosine - The Lingawaited Therapy for visceral leishmaniasis?. N Engl J Med 1999; 9: 1840-1842.
170. Herwaldt B. ACL in U.S. Travelers. Ann Int Med 1993; 118(10): 779-784.
171. Herwaldt B. Leishmaniasis. Lancet 1999;354:1191-1199
172. Ilg T. Lipophosphoglycan of the protozoan, parasite Leishmania: stage and species - specific importance for colonization of the sandfly vector, transmission and virulence to mammals. Med Microbiol Immunol 2001; 190: 13-17.
173. Iraji F. Comparison of intralesionally injected zinc sulfate with meglumine antimoniate in the treatment of acute CL. Dermatology 2004; 209(1): 46-49. (Pubitemid 39179105)
174. Iraji F, Sadeghinia A. Efficacy of paromomycin ointment in the treatment of CL: results of a double-blind, randomized trial in Isfahan, Iran. Ann Trop Med Parasitol. 2005; 99(1): 3-9.
175. Jappe U. Unusual. Skin Infections in Military Personnel. Clinics in Derm 2002; 20: 425-434.
176. Jauréguiberry S, Graby G, Caumes E. Efficacy of short Course Intramuscular Pentamidine Isethionate Treatment on Old world Cutaneous Leishmaniasis in 2 Patients. Clin Infect Dis 2006; 42: 1812-1813. (Pubitemid 43839458)
177. Jolliffe D. CL from belize - treatment with ketoconazolc. Clin Exp Dermatol 1.986; II: 62-68.
178. Junaid A. Treatment of CL with infrared heat. IntJ Dermatol 1986; 2,5(7): 470-471.
179. Just S, Schcpers G, Piotrowski M, Saint S, Kauffman C. Improving the safety of intravenous admixtures: Lessons learned from a pentostam overdose. J Qual Pat Safety 2006; 32(7): 366-372.
180. Kafetzis D, Maltezou H. Visceral leishmaniasis in paediatrics. Current Opinion Infect Dis 2002; 15(3): 289-294.
181. Kellum R et al. Treatment of CL with an intralesional antimonial drug (Pentostam). J Am Acad Dermatol 1986; 15: 620-622.
182. Kliarfi M. Childhood Leishmaniasis: Report of 106 cases. Derma Online J 2005; 10(2).
183. Khatami A, Firooz A, Gorouhi F, Dowlati Y. Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials. J Am Acad Dermatol 2007; 57(2): 335-364.
184. Kochar D1 Saini G, Kochar S, Sirohi P Bumb R, Mehta R, Purohit S. A. double blind, randomized placebo controlled trial of rifampicin with omeprazole in the treatment of human CL. J Vect Borne Dis 2006; 43: 161-167. (Pubitemid 44901458)
185. Kochar D, Aseri S, Sharma B, Bumb R, Mehta R, Purothi S. The Role of rifampicin in the management of CL. Association of Physicians 2000; 93: 733-737.
186. Konecny P, Stark D. An Australian case of New World cutaneous leishmaniasis. Med J Aust 2007; 186(6): 315-317.
187. Krause G. Topical Paromoycin/ Methylbenzethonium Chloride Plus Parenteral Meglumine Antimonate as Treatment of ACL: Controlled Study. Clin Infect Dis 1999; 29: 466-467.
188. Krause G. Topical, treatment of ACL with paromomycin and methylbenzethonium chloride: a clinical study under field conditions in Ecuador. Trans R Soc Trop Med. Hyg 1994; 88: 92-94. (Pubitemid 24068862)
189. Kumaresan M, Kumar P. Localized CL in South India: Successful treatment with Ketoconazole. Ind J Derm 2007; 73(5): 361-362.
190. Lai A Fat E, Vrede M, Soctoscnojo R, Lai A. Fat R. Pentamidine the drug of choisc for the treatment of CL in Surinam. Int J Dermatol 2002; 41: 796-800.
191. Lainson R. Leishmania mexicana: the epidemiology of dermal, leishmaniasis in British, Honduras. Trans R Soc Trop Med Hyg 1965; 57: 242-265.
192. Lambertucci J, Franca B, Queiroz E. Acute pancreatitis caused, by meglumine antimoniate given for the treatment of visceral leishmanisis. Rev Soc Bras Med Trop 2004; 37: 74-75. (Pubitemid 38279915)
193. Larabi M, Yardley V, Loiseau P, Appel M, Legrand P, Gulik A, Bories C, Croft S, Barratt G. Toxicity and Antileishmanial Activity of a New Stable Lipid Suspension of Amphotericin B. Antimicrob Agents Chemother 2003; 47(12): 3774-3779.
194. Lawn S. NWCL in returned, travellers: treatment failures using intravenous sodium stibogluconate. Trans R Soc Trop Med Hyg 2003; 97: 443-445.
195. Lawn S, Armstrong M, Chilton D, Whitty C. Electrocardiographic and
196. Lawn S, Whethman J, Chiodini P, Kanagalingam J, Watson. J, Behrens R, Lockwood D. New world mucosal and CL: an emerging health problem among British travellers. QualJM 2004; 97(12): 781-788.
197. Layegh P, Yazdanpanah M, Vosugh E, Pezeshkpoor F, Shaken M, Moghiman T. Efficacy of Azithromycin versus systemic meglumine antimoniate (Glucantime) in the treatment of CL. Am J Trop Med Hyg 2007; 77(1): 99-101. (Pubitemid 351844358)
198. Leibovici V, Aram H. Cryotherapy in acute cutaneous Leishmaniasis. Int J Dermatol 1986; 25(7): 473-475.
199. Lesho E. Nonhealing skin lesions in a sailor and a journalist returning from Iraq. Cleveland Clinic J Med 2005; 72(2): 93-105.
200. Lessa H, Machado P, Lima F, Cruz A, Baccllar O, Guerreiro J, Carvalho E. Successful treatment of refractory MCL with pentoxifylline plus antimon. Am J Trop Med Hyg 2001; 65(2): 87-89. (Pubitemid 32746963)
201. Levine N, CL treated with controlled localized heat. Arch Dermatol 1992; 128:759-761.
202. Lightburn E, Morand J, Meynard J, Kraemcr P, Chaudier B, Pages F, Garnotcl E, Patte J, Banzet S, Dampierre H, Lepage J, Morillon M, Botin J, Hovette P, Chouc C. Management of ACL. Outcome apropos of 326 cases treated with, high-dose pentamidine isethionate (Thérapeutique des leishmanioses tegumentaircs du nouveau monde experience a propos de 326 castraites par isethionate de pantamidine a fortes doses). Med Trop (Mars) 2003; 63(1): 35-44.
203. Llanos-Cuentas A, Echevarri a J, Seas C, Chang E, Cruz M, Alvarez E, Rosales E, Campos P, Bryceson A. Parenteral aminosidine is not effective for Peruvian MCL. Am J Trop Med Hyg 2007; 76(6): 1128-1131.
204. Llanos-Cuentas A, Echevarria J, Cruz M, La Rosa A, Campos P, Campos M, Franke E, Berman J, Modabber F, Marr J. Efficacy of Sodium stibogluconate alone and in Combination with Allopurinol for Treatment of Mucocutaneous Leishmaniasis. Clin Infect Dis 1997; 25: 677-684.
205. Lobo I, Soares M, Correia T, Freitas L, Oliveira M, Nakatani M, Netto E, Badaro R, David J. Heat therapy for CL elicits asystemic cytokine response similar to that of antimonial (Glucantime) therapy. Trans R Soc Trop Med Hyg 2006; 100: 642-649.
206. Loiseau P, Bories C. Recent strategies for the chemotherapy of visceral leishmaniasis. Current Opinion in Infect Dis 1999; 12: 559-564. (Pubitemid 30058148)
207. Low-A Chee R Rose P, Ridley D. An outbreak of CL in Guyana: epidemiology, clinical and laboratory aspects. Ann Trop Med Parasitol 1983; 77(3): 255-260.
208. Lucas C, Franke E, Cachay I, Tejada A, Cruz M, Kreutzer R, Barker D, McCann S, Watts D. Geographic distribution and clinical description of Leishmaniasis in Peru. Am J Trop Med Hyg 1.998; 59(2): 312-317.
209. Machado P, Lcssa H, Guimaraes L, Bang H, Ho J, Carvalho E. Oral. Pentoxifylline combined with pentavalcnt antimony: a randomized trial for MCL. Clin Infect Dis 2007; 44: 788-793.
210. Machado-Coelho G, Caiaffa W, Genaro O, Magahaes P, Mayrink W Risk factors for mucosal manifestation of American CL. Trans R Soc Trop Med Hyg 2005; 99: 55-61. (Pubitemid 39517037)
211. Machado-Pinto J, Pinto J, da Costa C, Genaro O, Marques M, Modabber F, Mayrink, W Immunochemothcrapy for CL: a controlled trial, using killed Leishmania (L.) amazonensis vaccine plus antimonial. Int J Dermatol 2002; 41: 73-78.
212. Macnair A et al. Hepatitis and ketoconazole therapy. Br Med J 1981; 283: 1058-1060.
213. Magill AJ, Grogl M, Casser RA Jr, Sun W, Oster CN. Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm. N Engl J Med. 1993; 328(19): 1383-1387. (Pubitemid 23131391)
214. Magill A. CL in the returning traveller. Infect Dis Clin N Am 2005; 19: 241-266.
215. Mahajan V, Sharma N. Therapeutic options for CL. J Derm Treat 2007; 18:97-104.
216. Markle W, Makhoul K. CL: Recognition and Treatment. Am Fam Phys 2004; 69(6): 1455-1.460.
217. Marovich M, Lira R Shepard M, Fuchs G, Kruetzer R, Nutmann T, Neva F. Leishmaniasis Recidivans Recurrence after 43 Years: A Clinical and Immunologic Report after Successful Treatment. Clin Infect Dis 2001; 33: 1076-1079. (Pubitemid 32907113)
218. Marques MJ, Volpini AC, MachadoCoelho GL, Machado-Pinto J, da Costa CA, Mayrink W, Genaro O, Romanha AJ. Comparison of polymerase chain reaction with other laboratory methods for the diagnosis of American cutaneous leishmaniasis: diagnosis of cutaneous leishmaniasis by polymerase chain reaction. Diagn Microbiol Infect Dis 2006; 54(1): 37-43. (Pubitemid 41815186)
219. Marsden P et al. High continuous antimony therapy in two patients with unresponsive MCL. Trans R Soc Trop Med Hyg 1985; 34: 710-713. (Pubitemid 16237014)
220. Martinez S. Allopurinol in the Treatment of ACL. N Engl J Med 1992; 326: 741-744.
221. Martinez S, Looker D, Berens R, Marr J. The synergistic action of pyrazolopyrimidincs and pentavalent antimony against Leishmania donovani and L. braziliensis. Am J Trop Med Hyg 1988; 39(3): 250-255. (Pubitemid 18242399)
222. Matlashewski G. Leishmania infection and virulence. Med Microbiol Immunol. 2001; 190:37-42.
223. McBride MO, Linney M, Davidson RN1 Weber JN. Pancreatic necrosis following treatment of leishmaniasis with sodium stibogluconate. Clin Infect Dis 199.5; 21(3): 710.
224. McMahon-Pratt D, Alexander J. Does the lcishmania major paradigm of pathogenesis and protection hold for the NWCL or the visceral disease?. Imun Rev 2004; 201: 206-224. (Pubitemid 39318454)
225. Mebrahtu Y, Lawyer P, Githure J, Were JB, Muigai R, Hendricks L, LeeuwenburgJ, Koech D, Roberts C. Visceral leishmaniasis unresponsive to pentostam caused, by Leishmania tropica in Kenya. Am J Trop Med Hyg 1989;41:289-294. (Pubitemid 19250154)
226. Mendonca M. Persistence of Leishmania Parasites in Scars after Clinical Cure of American CL: Is There a Sterile Cure?. J Infect Dis 2004; 189: 1018-1023. (Pubitemid 38373094)
227. Meyerhoff A. U.S. Food and Drug Administration. Approval, of AmBisome (Liposomal Amphotericin B) for Treatment of Visceral Leishmaniasis. Clin Infect Dis 1999; 28: 42-48.
228. Michalick M. Genero Lcishmania. Buchkapitel 31-72.
229. Minodier P, Noel G, Blanc P, Uters P, Retornaz K, Gamier J. Management of CL in adults and children. Med Trop (Mars) 2005; 65(5): 487-495.
230. Minodier P, Parola P. CL treatment. Trav Med Inf Dis 2007; 5: 150-158.
231. Miranda-Verástegui C, Llanos-Cuentas A1 Arévalo I, Ward B, Matlashewski G. Randomized, double-blind clinical trial of topical imiquimod 5 % with parenteral meglumine antimoniate in the treatment of CL in Peru. Clin Infect Dis 2005; 40: 1395-1403.
232. Mirzabeigi M, Farooq U, Baraniak S, Dowdy L, Ciancio G, Vincek V Reactivation of dormant CL infection in a kidney transplant patient. J Cut Path 2006; 33: 701-704. (Pubitemid 44536351)
233. Modabber F. Experiences with vaccines against CL: of men and mice. Parasitology 1989; 98: 49-60.
234. Modabber F, Buffet P, Torreele E, Milon G, Croft S. Consultative meeting to develop a strategy for treatment of CL. Review. Institute Pasteur, Paris. 13-15 June, 2006. Kinetoplastid Biology and Disease 2006; 1-24.
235. Mohebali M, Fotouhi A, Hooshmand B, Zarei Z, Akhoundi B, Rahnema A, Razaghian A, Kabir M, Nadim A. Comparison of Miltefosine and meglumine antimoniate for the treatment of zoonotic CL (ZCL) by a randomized clinical trial in Iran. Acta Tropica 2007; 103(1): 33-40.
236. Momeni AZ, Shafiei A, Emamjoeh M, Aminjavaheri M, Momeni A. Azithromycin is not effective in the treatment of old world cutaneous leishmaniasis. Eur J Dermatol 2006; 16(6): 701-702. (Pubitemid 46202981)
237. Momeni A1 Aminjavaheri M. Successful treatment of non-healing cases of CL, using a combination of meglumine antimoniate plus allopurinol. Eur J Dermatol 2003; 13(1): 40-43.
238. Momeni A, Aminjavaheri M. Treatment of recurrent CL. IntJ Dermatol 1995; 34(2): 129-133.
239. Momeni A, Aminjavaheri M, Omidghaemi M. Treatment of CL with Ketoconazole cream. J Derm Treat 2003; 14: 26-29.
240. Momeni A, Jalayer T, Emamjomeh M, Bashardost N, Ghassemi R, Meghdadi M, Javadi A, Aminjavaheri M,. Treatment of CL with itraconazole. Randomized double-blind study. Arch Dermatol 1996; 132(7): 784-786.
241. Momeni A, Reiszadae M, Aminjavaheri M. Treatment of CL with the combination of allopurinol and lowdose meglumine antimonate. Int J Dermatol 2002; 41(7): 441-443. (Pubitemid 34905080)
242. Moreira S. Therapeutic trial in experimental tegumentary leishmaniasis caused by Leishmania (Leishmania) amazonensis. A comparative study between mefloquine and aminosidine. Rev Soc Bras Med Trop 2000; 33(4): 377-382.
243. Morelli P. Itraconazol can be effective in the Treatment of Sporotrichoid Leishmaniasis. J Travel Med 2004; 11: 328-330. (Pubitemid 39482179)
244. Morgan D, Guimaraes L, Machado P et al. CL during Pregnancy: Exuberant Lesions and potential fetal complications. ClinI.nf.Dis 2007; 45: 478-482.
245. Morizot G, Delgiudice P, Caumes E, Laffittc E, Marty P, Dupuy A, Sarfati C et al. Healing of OWCL in travel- lers treated with Fluconazole: drug effect or spontaneous evolution?. Am J Trop Med. Hyg 2007; 76(1): 48-52.
246. Morris-Jones S. Medical Mystera: Painless Ulcers - The Answer. N Engl J Med 2004; 350(22): 2313-2314.
247. Mujtaba G. Weekly vs. fortnightly intralesional, meglumine antimoniate in CL. Int J Dermatol 1999; 38(8): 607-609.
248. Murray H. Advances in. Leishmaniasis. Lancet 200,5; 366: 1561-1577.
249. Murray H. Treatment of visceral leishmaniasis in 2004. Am J Trop Med Hyg 2004; 71 (6): 787-794.
250. Musa AM et al. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent postkalaazar dermal leishmaniasis (PKDL). Ann Trop Med Parasitol 2005; 99: 563-569.
251. Myler P. The Leishmania genome project: new insights into gene organization and function. Med Microbiol Immunol 2001; 190:9-12. (Pubitemid 33079349)
252. Nacher M, Carme B, Sainte Marie D, Couppie P, Clyti E, Guibert P, Pradinaud R Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of CL in French Guiana. Ann Trop Med Parasitol 2001; 95(4): 331-336. (Pubitemid 32575486)
253. Nagaty I. Treatment of CL Patients with pentostam via intraleasional infiltration. J Egypt Soc Parasitol. 2000; 30(1): 177-182.
254. Nakayama H, Loiseau P, Bories C, Torres de Ortiz S, Schinini A, Serna E, Rojas de Arias A, Fakhfakh M, Franck X, Figadere B, Hocquemiller R, Fournet A. Efficacy of orally adminstered 2-substituted quinolines in experimental murine cutaneous and visceral leishmaniases. Antimicrob Agents Chemother 2005; 49(12): 4950-4956. (Pubitemid 41778905)
255. Nassiri K, Firooz A, Khamesipour A, Nilforoushzadeh M, Hejazi H, Bouzari N, Dowlati Y A randomized, double-blind, placebo controlled clinical trial of itraconazole in the treatment of CL. JEADV 2005; 19: 80-83. (Pubitemid 40268145)
256. Navin T Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating CL in Guatemala. J Infect Dis 1992; 165(3): 528-534.
257. Navin T Placebo-controlled clinical of meglumine antimonate (glucantime
258. vs. localized, controlled heat in the treatment of CL in Guatemala. Am J Trop Med. Hyg 1990; 42(1): 43-50.
259. Neal R Allen S, McCoy N, Olliaro P, Croft S. The sensitivity of Leishmania Spezies to aminosidine. J Antimlcrob Chcm 1995; 35: 577-584.
260. Neal R, Murphy A, Olliaro P, Croft S. Aminosidine ointments for the treatment of experimental CL. Trans R Soc Trop Med Hyg 1994; 88: 223-225.
261. Netto E, Marsden P, Llanos-Cuetas E, Costa J, Cuba C, Barreto A, Badaro R, Johnson W, Jones T Lmg-term follow-up of patients with Leishmania (Viannia) braziliensis infection and treated with Glucantime. Trans R Soc Trop Med Hyg 1990; 84: 367-370. (Pubitemid 20204315)
262. Neva F, Petersen E, Corsey R Bogaert H, Martinez D. Observations on local heat treatment for CL. Am J Trop Med. Hyg 1984; 33(5): 800-804.
263. Neva F, Ponce C, Ponce E, Kreutzer R Modabber F, Olliaro P. Non-ulcerative CL in Honduras fails to respond to topical paromomycin. Trans R Soc Trop Med Hyg 1997; 91: 473-475.
264. Norton SA, Frankenburg S, Klaus SN. Cutaneous leishmaniasis acquired during military service in the Middle East. Arch Dermatol. 1992; 128(1): 83-87.
265. Ojha R, Cervantes D, Fischbach. L. Oral pentoxifylline and pentavalent antimony for treatment of Leishmaniasis: promising but inconclusive evidence of superiority, compared with antimony monotherapy. Clin Infect Dis 2007; 4,5: 1104-1105. (Pubitemid 47580364)
266. Oliveira-Neto M., High and Low Doses of Antimony in American CL. A Five Years Follow-up Study of 15 Patients. Mem Inst Oswaldo Cruz 1996; 91(2): 207-209.
267. Oliveira-Neto M. Intralesional therapy of American CL with pentavalent antimony in Rio de Janeiro, Brazil - an area of Leishmania braziliensis transmission. Int J Dermatol 1997; 36(6): 463-468. (Pubitemid 27319639)
268. Oliveira de Sá T, Capp Neto M. Action of pentoxifylline on experimental cutaneous leishmaniasis due to Leishmania (Leishmania) amazonensis. Mem Inst Oswaldo Cruz 2000; 95(4): 477-482.
269. Oliveira-Neto M. Tratamentos antimoniais da leishmaniose. Rev Soc Bras Med Trop 2005; 38(5): 446-447.
270. Oliveira-Neto M, da Silva Mattos M. An alternative antimonial schedule to be used in CL when high doses of antimony are undesirable. Rev Soc Bras Med Trop 2006; 39(4): 323-326. (Pubitemid 44476857)
271. Oliveira-Neto M, Schubach A, Mattos M, Goncalves S, Pirmez C. Intralesional therapy of ACL with pentavalent antimony in Rio dc Janeiro, Brazil - an area of Leishmania (V.) braziliensis transmission. Int J Dermatol 1997; 36: 463-468.
272. On J. Topical Chemotherapy of CL. Parasitology Today 1988; 4(3): 76-81.
273. Oster C et al. ACL: a comparison, of three sodium stibogluconate treatment schedules. Am J Trop Med Hyg 1985; 34: 856-860.
274. Ozgoztasi O, Baydar I. A randomized clinical trial of topical paromomycin versus oral ketoconazole for treating CL in Turkey. Int J Dermatol 1997; 36(1): 61-63. (Pubitemid 27139758)
275. Palacios R, Osorio L, Grajales L, Ochoa M. Treatment failure in children in a randomized clinical treal with 10 and. 20 days of Meglumine Antimoniate for CL due to Leishmania Viannia species. Am J Trop Med Hyg 2001; 64(3,4): 187-193. (Pubitemid 32565849)
276. Panagiotopoulos A, Stavropoulos P, Hasapi V, Papakonstantinou A, Petridis A, Katsambas A. Treatment of CL with cryosurgery. Int J Dermatol. 2005; 44(9): 749-752
277. Paradisi A et al. Atypical multifocal cutaneous leishmaniasis in an immunocompetent patient treated by liposomal amphotericin. BrJ Infect 2005; 51: 261-264. (Pubitemid 43008973)
278. Passos V. Leishmaniose tegumentalna Regiao Metropolitana de Belo Horizonte: aspectos cliinicos, laboratoriais terapeuticos e evolutivos (19891995). Rev Soc Bras Med. Trop 2001; 34(1): 5-12.
279. Pearson R. Leishmania Species: VL, CL and MCL. Infect Dis Etiolog Agents 2831-2845.
280. Ponce C, Ponce E, Morrison A, Cruz A, Kreutzer R, McMahon-Pratt D, Neva F. Leishmania donovani chagasi: new clinical variant of CL in Honduras. Lancet 1991; 337(8733): 67-70.
281. Pradinaud R. CL. Society for Dermatol in the Trop 2005.
282. Prata A, Silva-Vergara ML, Costa L, Rocha A, Krolewiecki A, Silva JC, de Paula EV, Pimenta Junior FG, Giraldo LE. Efficacy of azithromycin in the treatment of cutaneous leishmaniasis. Rev Soc Bras Med Trop 2003; 36(1): 65-69. (Pubitemid 36648215)
283. Rahman S, Bari A, MumtazN. Miltefosine in cutaneous leishmaniasis. J Coll Physicians Surg Pak 2007; 17(3): 132-135.
284. Rajab M. Intralesional Treatment of CL with Sodium Stibogluconate Antimony. IntJ Dermatol 1993; 32(8): 610-612.
285. Ramirez J, Agudelo S, Muskus C, Alzate J, Berberich C, Barker D, Vélez I. The method used to sample ulcers influences the diagnosis of CL. Trans R Soc Trop Med Hyg 2002; S1 : 169-171.
286. Ripp C et al. Liposomal amphotericin B treatment of cutaneous leishmaniasis contracted in Djibouti and resistant to meglumine antimoniate. Bull Soc 2003; 96: 209-211.
287. Rawlins S. ACL in Guyana, South America. Ann Trop Med Parasitol 2001; 95(3): 245-251.
288. Reithinger R Efficacy of Thermotherapy to Treat CL Caused by Leishmania tropica in Kabul, Afghanistan: A Randomized, Controlled Trial Clin. Infect Dis 2005; 40: 1148-1158.
289. Reithinger R, Coleman P. Treating CL patients in Kabul, Afghanistan: cost-effectiveness of an operational, program in a complex emergency setting. BMC 2007; 7: 1-9. (Pubitemid 46243435)
290. Reithinger R, Dujardin J, Louzir H, Pirmez C, Alexander B, Brooker S. CL. TLID 2007; 7: 581-596.
291. Reyburn H. The prolonged epidemic of anthroponotic CL in Kabul, Afghanistan: bringing down the neighbourhood. Trans R Soc Trop Med Hyg 2003; 97: 170-176.
292. Ribeiro C, Sampaio J, Cardoso D, Sampaio R. A comparative study between the efficacy of pentamidine iosthionate given in three dosis for a week and. N-methyl-glucamine in a dose of 20 mgSbV/day for 20 days to treat CL. Rev Soc Bras Med. Trop 2003; 36(3): 365-371.
293. Rijai S, Chappius F, Singh R, Bovier P, Acharya B, Karki B, Das M, Desjeux P, Loutan L, Koirala S. Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. Trans R Soc Trop Med Hyg 2003; 97: 350-354. (Pubitemid 39185896)
294. Rijai S, Chappuis S, Singh R Boelaert M, Loutan L, Koirala S. Sodium stibogluconate cardiotoxicity and safety of generics. Trans R Soc Trop Med Hyg 2003; 97: 597-598. (Pubitemid 40590103)
295. Ritmeijcr K, Dejenie A, Assefa Y, Hundie T, Mesure J, Boots G, den Boer M, Davidson. R. A comparison of Miltefosinc and sodium stibogluconate for treatment of VL in an Ethiopian population with high prevalence of HIV infection. CID 2006; 43: 357-364. (Pubitemid 44078909)
296. Robert W, Rainley P. Antilcishmanial activity of sodiumstibogluconate fractions. Antimicrob Agents Chemother 1993; 37(9): 1842-1846.
297. Roberts M. Current understandings on the immunology of leishmaniasis and recent developments in prevention and treatment. Br Med Bull 2006; 75-76: 115-130. (Pubitemid 44725919)
298. Robinson RJ, Agudelo S, Muskus C, Alzate JF, Berberich C, Barker DC, Velez ID. The method used to sample ulcers influences the diagnosis of cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 2002; 96(Suppl. 1): S 169-171. (Pubitemid 34846603)
299. Rojas R, Valderrama L, Valderrama M, Varona MX, Ouellette M, Saravia NG. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. J Infect Dis. 2006; 193(10): 1375-1383. (Pubitemid 43673385)
300. Romero G. Comparison of CL due to Leishmania (Viannia) Braziliensis and L. (V) Guyanensis in Brazil: Therapeutic response to Meglumine Antimoniate. Am J Trop Med Hyg 2001; 65(5): 456-465.